The Medical Letter on Drugs and Therapeutics
Olaratumab (Lartruvo) for Soft-Tissue Sarcoma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Olaratumab (Lartruvo – Lilly), a platelet-derived growth factor receptor alpha (PDGFR-α) blocking monoclonal antibody, has received accelerated approval from the FDA for use in combination with the anthracycline doxorubicin for first-line treatment of adults with soft-tissue sarcoma histologic subtypes considered susceptible to anthracyclines. Approval is limited to locally advanced or metastatic soft-tissue sarcomas that are not amenable to curative radiotherapy or surgery, and is contingent on verification of clinical benefit in a confirmatory phase 3 trial.

STANDARD TREATMENT — Surgical resection, with or without adjuvant radiation and/or chemotherapy, is the treatment of choice for localized soft-tissue sarcoma. Doxorubicin with or without the alkylating agent ifosfamide is the standard first-line treatment for metastatic disease. Doxorubicin remains the most effective single drug used for treatment ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Olaratumab (Lartruvo) for Soft-Tissue Sarcoma (online only)
Article code: 1527d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian